drugset / Trial / NCT07096609
Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients
NaSingle-groupOpen-labelTreatment
Summary
The aim of this study is to evaluate the safety and efficacy of lenvatinib in patients with metastatic or advanced GIST who have failed at least imatinib, sunitinib, and regorafenib treatment.
Timeline
- Start
- 2025-10-29
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |
| Subject | Lenvatinib | Small molecule | 12 mg | Oral |